Latest 8-K filings

Energy Vault Holdings, Inc. reported a strong second quarter of 2026 with revenue up 104% year-over-year, significantly expanded gross margins, and a record contract backlog of $2 billion, leading to raised full-year revenue and gross margin guidance.

NextNav Inc. announced its second quarter 2026 financial results, showcasing strengthened partnerships, significant debt reduction, and a robust cash position.

Black Rock Coffee Bar announced robust second quarter 2026 financial results, featuring 25.0% total revenue growth and a 403.3% increase in net income.

BridgeBio Oncology Therapeutics reported Q2 2026 financial results, highlighting advancements in its clinical programs for RAS-pathway malignancies and a cash runway extending into 2028.

Grove Collaborative Holdings, Inc. received a notice from the NYSE for failing to meet minimum market capitalization and stockholders' equity requirements, necessitating a business plan to regain compliance.

Rocket One Inc. received a Nasdaq delisting warning for failing to meet minimum bid price requirements, while simultaneously announcing its acceptance into the Seagate Partner Program to bolster its AI infrastructure strategy.

Anterix announced its first quarter fiscal year 2027 results, reporting approximately $33.1 million in contracted proceeds and a $10.7 million gain on broadband license exchanges, while maintaining a debt-free balance sheet with $116.0 million in cash.

B&G Foods reported a 9.7% decrease in net sales for Q2 2026 to $383.3 million and a net loss of $4.0 million, though adjusted EBITDA increased by 4.2% to $60.4 million.

Gain Therapeutics announced FDA IND acceptance for rexaceract's Phase 2 trial and reported Q2 2026 financial results, highlighting pipeline progress despite a net loss.

IZEA Worldwide announced its second quarter 2026 financial results, reporting $5.8 million in revenue, a 36% decrease year-over-year, and a net loss of $0.7 million.

Erasca, Inc. announced second quarter 2026 financial results and business updates, highlighting progress in its ERAS-0015 and ERAS-4001 clinical programs and a substantial capital raise.

Snail, Inc. reported its second quarter 2026 financial results, showing a year-over-year revenue decrease but a substantial improvement in net loss, alongside updates on its ARK franchise and new AI ventures.

East West Ave Acquisition Corp. announced that its common stock and rights will begin trading separately on August 14, 2026, offering investors more trading flexibility.

Sanara MedTech Inc. announces an Agreement and Plan of Merger with MiMedx Group, Inc., detailing terms for acquisition and shareholder consideration.

Stereotaxis announced robust second-quarter 2026 results, with robotic catheter revenue surging 270% sequentially, alongside strategic acquisitions and positive future outlook for profitability.

AnaptysBio, Inc. announced the outcomes of its 2026 Annual Meeting of Stockholders, including the election of directors, ratification of its auditor, and approval of an amendment to its equity incentive plan.

Immunome announced its second quarter 2026 financial results, highlighting the FDA's acceptance of the New Drug Application for varegacestat with a PDUFA target action date of April 28, 2027, and providing updates on its clinical pipeline.

The Boston Beer Company has initiated a 10b5-1 plan to repurchase up to $25 million of its Class A Common Stock.

Chaince Digital Holdings Inc. announced a registered direct offering expected to raise approximately $16.2 million to fund its digital asset, tokenization, and capital markets strategies.

Optex Systems Holdings reported a decrease in Q3 fiscal 2026 revenue to $9.7 million from $11.1 million year-over-year, primarily due to delayed contract awards and delivery schedules, though gross margins improved significantly.

Bolt Biotherapeutics reported Q2 2026 financial results, highlighting ongoing BDC-4182 Phase 1/2 study progress with initial data expected in Q3 2026, while noting a significant decrease in collaboration revenue and an increase in net loss.

Kyverna Therapeutics announced second quarter 2026 financial results, highlighting FDA RMAT designation for miv-cel in naSPMS and progress on BLA submission for SPS.

Achieve Life Sciences announced a significant private placement and leadership enhancements, while also detailing a delay in its cytisinicline New Drug Application resubmission due to manufacturing observations.

enGene Therapeutics Inc. hosted a KOL event on August 11, 2026, to present market research on non-muscle-invasive bladder cancer (NMIBC) and discuss its investigational therapy, detalimogene.

AN2 Therapeutics reported Q2 2026 results, detailing progress in Phase 2 trials for polycythemia vera and Chagas disease, alongside pipeline expansion and increased R&D spending.

Federal Realty OP LP has issued $460 million in 3.500% Exchangeable Senior Notes due 2031, alongside capped call transactions to mitigate dilution.

Fold Holdings, Inc. announced its second quarter 2026 financial results, reporting $6.1 million in revenue and a net loss of $9.7 million, while highlighting progress in its credit card program and debt reduction.

Onfolio Holdings Inc. shareholders have overwhelmingly approved critical proposals at the 2026 Annual Meeting, including director elections, auditor ratification, and significant corporate actions related to stock issuance and authorized share increases.

Smart Sand, Inc. announced record second quarter 2026 results, including record sales volumes and revenues, alongside a planned leadership transition for its Chief Financial Officer.

Apogee Therapeutics stockholders overwhelmingly approved the merger agreement with AbbVie, paving the way for the acquisition.